Membranous Nephropathy | Disease Landscape & Forecast | G7 | 2025
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Despite being one of the leading causes of nephrotic syndrome in nondiabetic adults, pMN does not have an approved therapy. Current treatment involves the use of off-label therapies to alleviate clinical symptoms and pMN complications and to delay the onset of end-stage renal disease. However, our understanding of the disease is making major strides. The discovery of PLA2R as a target antigen in almost 80% of pMN patients and the introduction of rituximab in the treatment algorithm exemplify the evolving concepts to manage the disease. Over the 2024-2034 period, we anticipate the pMN therapy market to radically transform through the launch of several therapies. Next-generation CD20- and CD38-targeting antibodies as well as BTK inhibitors, are some leading candidates looking to capture pMN drug approval.
Questions answered
- What percentage of pMN patients receive drug treatment? How do physicians use current off-label therapies to treat the disease?
- What are KOLs’ views of late-phase candidates (Roche’s obinutuzumab, Biogen’s felzartamab, BeOne medicines’ zanubrutinib)?
- How will emerging therapies influence the treatment landscape and affect prescribing decisions?
- What are the pMN therapy market’s key drivers and constraints, and how will the market evolve over the forecast period?
- What are the unmet needs in the treatment of pMN, and how likely are they to be fulfilled during the forecast period?
Geography: United States, EU5, Japan
Primary research: Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of pMN by country, clinically and market relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key membranous nephropathy therapies through 2034, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
